Stocks · News reference

B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18

Aug 12, 2026, 4:50 PMBenzinga Newsdesk

B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 12, 2026, 4:04 PMBenzinga Newsdesk
Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16
Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
Read original at benzinga
FENC
BenzingaAug 11, 2026, 2:51 PMBenzinga Newsdesk
Fennec Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Read original at benzinga
FENC
BenzingaAug 11, 2026, 11:03 AMBenzinga Newsdesk
Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of $(0.11) per share
Read original at benzinga
FENC TSX:FRX